RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:The Immunotherapy for Colorectal Cancer, Lung Cancer and Pancreatic Cancer.
The Immunotherapy for Colorectal Cancer, Lung Cancer and Pancreatic Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫治疗是一种新型的抗癌方法,其机制与传统治疗不同。由于为癌症患者提供了更好或替代的选择,它已成为一种重要的策略。近年来,免疫治疗越来越多地被批准用于癌症治疗;然而,它存在各种局限性;例如,它仅适用于特定患者,在大多数情况下响应率仍然较低等。结直肠癌、肺癌和胰腺癌在大多数国家被称为三大致死性癌症。在这篇综述中,我们讨论了这三种癌症的免疫治疗,并考虑了免疫治疗的选择、前景和局限性。免疫治疗的发展应侧重于发现生物标志物以筛选合适的患者、肿瘤新靶点、新辅助免疫治疗以及免疫治疗与传统治疗方法的结合。我们可以预期,免疫治疗有可能发展成为晚期癌症或对传统方法反应不佳患者的最佳疗法之一。
Immunotherapy is a novel anti-cancer method which employs a different mechanism to conventional treatment. It has become a significant strategy because it provides a better or an alternative option for cancer patients. Recently, immunotherapy has been increasingly approved for the treatment of cancer; however, it has various limitations; for instance, it is only suitable for specific patients, the response rate is still low in most cases, etc.
Colorectal cancer, lung cancer and pancreatic cancer are known as three major death-causing cancers in most countries. In this review, we discuss immunotherapeutic treatment for these three cancers, and consider the option, prospects and limitations of immunotherapy. The development of immunotherapy should focus on the discovery of biomarkers to screen suitable patients, new targets on tumors, neoadjuvant immunotherapy and the combination of immunotherapy with conventional therapeutic methods.
We can expect that immunotherapy potentially will develop as one of the best therapies for patients with advanced cancer or poor responses to traditional methods.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。